Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07332091 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
A Phase 2 study of Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis, sponsored by CSL Behring.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT07332091 is a Phase 2 study of Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis that is actively recruiting participants, run by CSL Behring. The registered enrollment target is 84 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT07332091, a Phase 2 study of Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis, is actively recruiting participants, sponsored by CSL Behring.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study to assess vamifeport in adult participants with homeostatic iron regulator gene-related hereditary hemochromatosis (HFE-HH). The primary objective of the study is to assess the effect of vamifeport treatment on magnetic resonance imaging (MRI)-based liver iron concentration (LIC) in adult participants with HFE-HH.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vamifeport
Study Locations (20)
Maryland
- Johns Hopkins University School of Medicine - Baltimore
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders - Bethesda
- James M. Stockman Cancer Institute - Frederick
California
- Infinity Clinical Trials - San Diego
- Medical Oncology Associates of San Diego - San Diego
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Duke University Medical Center (Duke South Clinics) -40 Duke Medicine Cir - Durham
Other
- Royal Brisbane and Women's Hospital - Brisbane
- Gallipoli Medical Research - Chandler
Arizona
- Banner MD Anderson - Gilbert
Florida
- Green Leaf Clinical Trials - Jacksonville
Indiana
- Indiana University Health University Hospital - Indianapolis
Louisiana
- Ochsner Medical Complex - High Grove - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2026-02-08 |
| Est. Completion | 2028-04-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07332091
The ClinicalTrials.gov registry entry for NCT07332091 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07332091 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Maryland, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07332091 about?
NCT07332091 is a clinical study titled "Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis". This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study to assess vamifeport in adult participants with homeostatic iron regulator gene-related hereditary hemochromatosis (HFE-HH). The primary objective of the study is to assess the effect...
What is the current status of trial NCT07332091?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2026-02-08. Estimated completion is 2028-04-06.
What conditions does trial NCT07332091 study?
This clinical trial studies the following conditions: Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis.
What interventions are being tested in trial NCT07332091?
The interventions under investigation include: Placebo (DRUG), Vamifeport (DRUG).
Who is sponsoring clinical trial NCT07332091?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07332091 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.